Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;31(6):678-684.
doi: 10.1111/iju.15437. Epub 2024 Feb 25.

Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data

Koichi Uemura  1 , Hiroki Ito  1 , Ryosuke Jikuya  1 , Takuya Kondo  1 , Tomoyuki Tatenuma  1 , Takashi Kawahara  2 , Yusuke Ito  1 , Mitsuru Komeya  1 , Kentaro Muraoka  1 , Hisashi Hasumi  1 , Hiroji Uemura  2 , Kazuhide Makiyama  1
Affiliations

Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data

Koichi Uemura et al. Int J Urol. 2024 Jun.

Abstract

Objective: In December 2021, enfortumab vedotin (EV), an antibody-drug conjugate directed against nectin-4, was approved in Japan as a new treatment after platinum-containing chemotherapy and PD-1/PD-L1 inhibitors. This study evaluated, using real-world data, the efficacy and safety of EV therapy in patients with metastatic urothelial carcinoma (mUC).

Materials and methods: Fifty-five patients with mUC who discontinued pembrolizumab therapy due to disease progression between June 2018 and April 2023 at Yokohama City University Hospital were evaluated retrospectively. Of the 55 patients, 25 received EV therapy (EV group) and 30 did not (non-EV group). All patients who underwent EV therapy were diagnosed with disease progression after the approval of EV in Japan.

Results: The median (range) follow-up period after pembrolizumab discontinuation was 6.3 (0.7-31.1) months. There were eight (32.0%) deaths due to cancer in the EV group and 27 (90.0%) in the non-EV group. The overall survival (OS) after pembrolizumab discontinuation was not reached in the EV group versus 2.6 months in the non-EV group (p < 0.001). A multivariate analysis revealed that EV therapy (EV vs. non-EV group; hazard ratio 0.26; 95% confidence interval 0.16-0.41; p < 0.001) was an independent prognostic factor for OS.

Conclusion: EV prolonged OS in mUC following pembrolizumab therapy in real-world data.

Keywords: enfortumab vedotin; metastatic urothelial carcinoma; multivariable analysis.

PubMed Disclaimer

References

    1. Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, et al. Japanese subgroup analysis of EV‐301: an open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med. 2023;12:2761–2771.
    1. Zschabitz S, Biernath N, Hilser T, Höllein A, Zengerling F, Cascucelli J, et al. Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real‐world patient cohort. Eur Urol. 2023;53:31–37.
    1. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022;128:1194–1205.
    1. Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, et al. Enfortumab vedotin following platinum‐based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real‐world Japanese cohort. Jpn J Clin Oncol. 2023;hyad170. https://doi.org/10.1093/jjco/hyad170
    1. Fukuokaya W, Koike Y, Yata Y, Komura K, Uchimoto T, Tsujino T, et al. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: a multicenter observational study. Int J Urol. 2023. https://doi.org/10.1111/iju.15368

MeSH terms

LinkOut - more resources